依那普利在代偿期肝硬化患者中的药代动力学。
The pharmacokinetics of enalapril in patients with compensated liver cirrhosis.
作者信息
Baba T, Murabayashi S, Tomiyama T, Takebe K
机构信息
Third Department of Internal Medicine, Hirosaki University School of Medicine, Japan.
出版信息
Br J Clin Pharmacol. 1990 Jun;29(6):766-9. doi: 10.1111/j.1365-2125.1990.tb03700.x.
Abstract
The possibility of an impaired hepatic de-esterification of enalapril to enalaprilat due to hepatic dysfunction was assessed in seven patients with compensated liver cirrhosis and 10 normal control subjects. The peak serum concentration and time to the peak serum concentration of enalaprilat, as well as the suppression of serum angiotensin converting enzyme activity, following a single oral dose of enalapril maleate (10 mg) were not different in the two groups. The elimination half-life of enalaprilat was related to renal function. The results suggest that hepatic biotransformation of the drug may not be disturbed in a clinically significant manner in patients with moderate hepatic dysfunction due to compensated liver cirrhosis.
摘要
在7例代偿期肝硬化患者和10名正常对照者中评估了因肝功能障碍导致依那普利肝去酯化生成依那普利拉受损的可能性。两组单次口服马来酸依那普利（10毫克）后，依那普利拉的血清峰值浓度、达到血清峰值浓度的时间以及血清血管紧张素转换酶活性的抑制情况均无差异。依那普利拉的消除半衰期与肾功能有关。结果表明，对于因代偿期肝硬化导致中度肝功能障碍的患者，该药物的肝生物转化可能不会受到具有临床意义的干扰。
相似文献
1
The pharmacokinetics of enalapril in patients with compensated liver cirrhosis.依那普利在代偿期肝硬化患者中的药代动力学。
Br J Clin Pharmacol. 1990 Jun;29(6):766-9. doi: 10.1111/j.1365-2125.1990.tb03700.x.
2
Kinetics and dynamics of enalapril in patients with liver cirrhosis.
Clin Pharmacol Ther. 1989 Jun;45(6):657-65. doi: 10.1038/clpt.1989.87.
3
Enalapril pharmacokinetics and ACE inhibition, following single and chronic oral dosing.依那普利单次及长期口服给药后的药代动力学及血管紧张素转换酶抑制作用
Int J Clin Pharmacol Ther. 1994 Mar;32(3):142-6.
4
Characterization of the pharmacokinetic and pharmacodynamic properties of the angiotensin-converting enzyme inhibitor, enalapril, in horses.血管紧张素转换酶抑制剂依那普利在马体内的药代动力学和药效学特性研究
J Vet Intern Med. 2004 Mar-Apr;18(2):231-7. doi: 10.1892/0891-6640(2004)18<231:cotpap>2.0.co;2.
5
Effect of cimetidine on the pharmacokinetics and pharmacodynamics of enalapril in normal volunteers.西咪替丁对正常志愿者中依那普利药代动力学和药效学的影响。
J Cardiovasc Pharmacol. 1988;12(5):512-9. doi: 10.1097/00005344-198811000-00003.
6
Pharmacokinetics and pharmacodynamics of enalapril and its active metabolite, enalaprilat, at four different doses in healthy horses.依那普利及其活性代谢产物依那普利拉在健康马匹中四种不同剂量下的药代动力学和药效学
Res Vet Sci. 2014 Aug;97(1):105-10. doi: 10.1016/j.rvsc.2014.06.006. Epub 2014 Jun 12.
7
Bioequivalence study of two enalapril maleate tablet formulations in healthy male volunteers. Pharmacokinetic versus pharmacodynamic approach.两种马来酸依那普利片剂在健康男性志愿者中的生物等效性研究。药代动力学与药效学方法。
Eur J Clin Pharmacol. 1996;50(5):399-405. doi: 10.1007/s002280050130.
8
Pharmacokinetics of enalapril and lisinopril in subjects with normal and impaired hepatic function.依那普利和赖诺普利在肝功能正常和受损受试者中的药代动力学。
J Hum Hypertens. 1989 Jun;3 Suppl 1:153-8.
9
Enalapril clinical pharmacokinetics and pharmacokinetic-pharmacodynamic relationships. An overview.依那普利的临床药代动力学及药代动力学-药效学关系概述
Clin Pharmacokinet. 1993 Oct;25(4):274-82. doi: 10.2165/00003088-199325040-00003.
10
The kinetic profiles of enalapril and enalaprilat and their possible developmental changes in pediatric patients with congestive heart failure.
Clin Pharmacol Ther. 1994 Aug;56(2):160-8. doi: 10.1038/clpt.1994.119.
引用本文的文献
1
Simultaneously Predicting the Pharmacokinetics of CES1-Metabolized Drugs and Their Metabolites Using Physiologically Based Pharmacokinetic Model in Cirrhosis Subjects.使用基于生理的药代动力学模型同时预测肝硬化受试者中CES1代谢药物及其代谢物的药代动力学
Pharmaceutics. 2024 Feb 5;16(2):234. doi: 10.3390/pharmaceutics16020234.
2
Clinical pharmacokinetics of vasodilators. Part I.血管扩张剂的临床药代动力学。第一部分。
Clin Pharmacokinet. 1998 Jun;34(6):457-82. doi: 10.2165/00003088-199834060-00003.
3
Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update.肝病患者的临床药代动力学和药效学考量。最新进展。
Clin Pharmacokinet. 1995 Nov;29(5):370-91. doi: 10.2165/00003088-199529050-00005.
4
Enalapril clinical pharmacokinetics and pharmacokinetic-pharmacodynamic relationships. An overview.依那普利的临床药代动力学及药代动力学-药效学关系概述
Clin Pharmacokinet. 1993 Oct;25(4):274-82. doi: 10.2165/00003088-199325040-00003.
5
Metabolites of antihypertensive drugs. An updated review of their clinical pharmacokinetic and therapeutic implications.抗高血压药物的代谢产物。其临床药代动力学及治疗意义的最新综述。
Clin Pharmacokinet. 1991 Nov;21(5):331-43. doi: 10.2165/00003088-199121050-00002.
6
The treatment of hypertension in pregnancy. Clinical pharmacokinetic considerations.
Clin Pharmacokinet. 1991 Oct;21(4):233-41. doi: 10.2165/00003088-199121040-00001.
7
The pharmacokinetics of perindopril in patients with liver cirrhosis.培哚普利在肝硬化患者中的药代动力学。
Br J Clin Pharmacol. 1992 Mar;33(3):326-8. doi: 10.1111/j.1365-2125.1992.tb04045.x.
8
Enalapril. A reappraisal of its pharmacology and therapeutic use in hypertension.依那普利。对其药理学及在高血压治疗中的应用的重新评估。
Drugs. 1992 Mar;43(3):346-81. doi: 10.2165/00003495-199243030-00005.
9
Acute effect of an alpha 1-adrenoceptor antagonist on urinary sodium excretion, plasma atrial natriuretic peptide, arginine vasopressin, and the renin-aldosterone system in healthy subjects.α1-肾上腺素能受体拮抗剂对健康受试者尿钠排泄、血浆心钠素、精氨酸加压素及肾素-醛固酮系统的急性影响。
Eur J Clin Pharmacol. 1992;43(1):17-21. doi: 10.1007/BF02280748.
本文引用的文献
1
Enalapril maleate and a lysine analogue (MK-521): disposition in man.马来酸依那普利与赖氨酸类似物（MK-521）：在人体中的处置情况
Br J Clin Pharmacol. 1982 Sep;14(3):357-62. doi: 10.1111/j.1365-2125.1982.tb01991.x.
2
Plasma enalapril levels and hormonal effects after short- and long-term administration in essential hypertension.原发性高血压患者短期和长期服用依那普利后的血浆依那普利水平及激素效应
Br J Clin Pharmacol. 1984;18 Suppl 2(Suppl 2):233S-239S, 241S. doi: 10.1111/j.1365-2125.1984.tb02602.x.
3
Pharmacokinetics of enalapril in normal subjects and patients with renal impairment.依那普利在正常受试者和肾功能损害患者中的药代动力学。
Br J Clin Pharmacol. 1986 Jan;21(1):63-9. doi: 10.1111/j.1365-2125.1986.tb02823.x.
4
Enalapril (MK421) activation in man: importance of liver status.依那普利（MK421）在人体中的激活：肝脏状态的重要性。
Br J Clin Pharmacol. 1985 May;19(5):701-4. doi: 10.1111/j.1365-2125.1985.tb02699.x.
5
Kinetics and dynamics of enalapril in patients with liver cirrhosis.
Clin Pharmacol Ther. 1989 Jun;45(6):657-65. doi: 10.1038/clpt.1989.87.
6
Enalapril. An update of its pharmacological properties and therapeutic use in congestive heart failure.依那普利。其药理特性及在充血性心力衰竭治疗应用的最新进展。
Drugs. 1989 Feb;37(2):141-61. doi: 10.2165/00003495-198937020-00004.
7
Effect of cimetidine on the pharmacokinetics and pharmacodynamics of enalapril in normal volunteers.西咪替丁对正常志愿者中依那普利药代动力学和药效学的影响。
J Cardiovasc Pharmacol. 1988;12(5):512-9. doi: 10.1097/00005344-198811000-00003.
Zotero 插件